[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100651415":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":21,"locations":27,"responsibleParty":43,"collaborators":20,"id":45,"slug":46,"hasResults":47,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":47,"sex":53,"minAge":54,"maxAge":55,"enrollmentInfo":56,"targetDuration":20,"studyType":59,"phases":60,"briefSummary":62,"conditions":63,"keywords":70,"overallStatus":29,"whyStopped":20,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":88},{"fullName":5,"class":6},"Peking University Third Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"68Ga-SorB PET\u002FCT Imaging","EXPERIMENTAL","Participants with suspected or confirmed malignant tumors will receive a single intravenous administration of 68Ga-SorB followed by PET\u002FCT imaging. Imaging findings will be compared with clinically indicated 18F-FDG PET\u002FCT performed within the predefined time window. No therapeutic intervention will be administered as part of this study.",[13],"Diagnostic Test: 68Ga-SorB PET\u002FCT",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DIAGNOSTIC_TEST","68Ga-SorB PET\u002FCT","Participants will receive a single intravenous administration of 68Ga-SorB (approximately 3.7 MBq\u002Fkg), followed by whole-body PET\u002FCT imaging approximately 60 minutes after injection. The imaging findings will be compared with clinically indicated 18F-FDG PET\u002FCT and reference standard findings to evaluate the safety, feasibility, biodistribution, tumor uptake, and exploratory diagnostic performance of 68Ga-SorB PET\u002FCT.",[9],null,[22],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},"Meixin Zhao","CONTACT","86-10-82264936","zhaomeixin.student@sina.com",[28],{"facility":5,"status":29,"city":30,"state":31,"zip":32,"country":33,"countryCode":34,"cosmosGeoPoint":35,"geoPoint":40,"contacts":41},"RECRUITING","Beijing","Beijing Municipality","100191","China","CN",{"type":36,"coordinates":37},"Point",[38,39],116.39723,39.9075,{"lat":39,"lon":38},[42],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},{"type":44,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR","100651415","68ga-sorb-petct-imaging-in-patients-with-solid-tumors-100651415",false,"NCT07760012","68Ga-SorB PET\u002FCT Imaging in Patients With Solid Tumors","A Prospective, Single-Center, Open-Label Exploratory Study of 68Ga-SorB PET\u002FCT Imaging for the Diagnosis of Sortilin-Positive Solid Tumors","SORB-PET","Inclusion Criteria:\n\n* \\- Adults aged 18 to 75 years.\n* Histologically confirmed or clinically suspected melanoma, hepatocellular carcinoma, lung cancer, breast cancer, pancreatic cancer, or ovarian cancer.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n* Adequate hematologic, hepatic, renal, and coagulation function:\n* White blood cell count ≥ 4.0 × 10\\^9\u002FL or absolute neutrophil count ≥ 1.5 × 10\\^9\u002FL;\n* Platelet count ≥ 100 × 10\\^9\u002FL;\n* Hemoglobin ≥ 90 g\u002FL;\n* PT or APTT ≤ 1.5 × upper limit of normal (ULN);\n* Total bilirubin ≤ 1.5 × ULN;\n* ALT and AST ≤ 2.5 × ULN (or ≤ 5 × ULN for participants with liver metastases);\n* ALP ≤ 2.5 × ULN (or ≤ 4.5 × ULN for participants with bone or liver metastases);\n* Blood urea nitrogen and serum creatinine ≤ 1.5 × ULN.\n* Normal cardiac function.\n* Estimated life expectancy of at least 12 weeks.\n* Willing and able to comply with study procedures and follow-up.\n* At least one measurable target lesion according to RECIST version 1.1.\n* Participants of childbearing potential agree to use effective contraception during the study and for 3 months after PET\u002FCT imaging.\n* Clinically indicated to undergo 18F-FDG PET\u002FCT for tumor evaluation.\n* Able to understand the study procedures and provide written informed consent.\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding women.\n* Severe dysfunction of major organs (including heart, liver, or kidney) that, in the investigator's judgment, would make participation inappropriate.\n* Inability to tolerate PET\u002FCT imaging or complete study follow-up.\n* Any other condition that, in the investigator's judgment, makes the participant unsuitable for the study.","ALL","18 Years","75 Years",{"count":57,"type":58},50,"ESTIMATED","INTERVENTIONAL",[61],"NA","This prospective, single-center, open-label exploratory diagnostic study aims to evaluate the safety, feasibility, and diagnostic performance of the novel Sortilin-targeted PET tracer 68Ga-SorB in patients with solid tumors. Eligible participants with confirmed or suspected melanoma, hepatocellular carcinoma, lung cancer, pancreatic cancer, breast cancer, or ovarian cancer will undergo 68Ga-SorB PET\u002FCT imaging. The imaging findings will be compared with standard-of-care 18F-FDG PET\u002FCT, using pathology results and\u002For clinical follow-up as the reference standard.\n\nThe primary objectives are to evaluate the safety and tolerability of 68Ga-SorB, assess imaging feasibility, and characterize tumor uptake using quantitative PET parameters, including SUVmax and tumor-to-background ratio (TBR). Secondary exploratory objectives include comparing lesion detection between 68Ga-SorB PET\u002FCT and 18F-FDG PET\u002FCT, assessing diagnostic sensitivity and specificity, evaluating imaging characteristics across different tumor types, and exploring the correlation between Sortilin expression and tracer uptake. This study will provide preliminary clinical evidence supporting the development of Sortilin-targeted molecular imaging and future theranostic applications.",[64,65,66,67,68,69],"Melanoma (Skin Cancer)","Hepatocellular Carcinoma","Lung Cancer","Breast Cancer","Pancreatic Cancer","Ovarian Cancer",[71,72,73,74,75,76,77,78],"Sortilin","68Ga-SorB","PET\u002FCT","Molecular Imaging","Diagnostic Imaging","Positron Emission Tomography","Radiotracer","Oncology","2026-08-09",{"date":81,"type":82},"2026-08-12","ACTUAL",{"date":84,"type":58},"2026-07-24",{"date":86,"type":58},"2028-12-31",{"name":5,"class":6},1]